Exendin-4 Improves Diabetic Kidney Disease in C57BL/6 Mice Independent of Brown Adipose Tissue Activation

J Diabetes Res. 2020 Feb 3:2020:9084567. doi: 10.1155/2020/9084567. eCollection 2020.

Abstract

Background: The role of exendin-4 in brown adipose tissue (BAT) activation was not very clear. This study is to verify the role of BAT involved in renal benefits of exendin-4 in diabetes mellitus (DM).

Methods: In vivo, C57BL/6 mice were randomly divided into nondiabetic (control) and diabetic groups (DM). The diabetic mice were randomized into a control group (DM-Con), BAT-excision group (DM+Exc), exendin-4-treated group (DM+E4), and BAT-excision plus exendin-4-treated group (DM+Exc+E4). The weight, blood glucose and lipids, 24 h urine albumin and 8-OH-dG, and renal fibrosis were analyzed. In vitro, we investigated the role of exendin-4 in the differentiation process of 3T3-L1 and brown preadipocytes and its effect on the rat mesangial cells induced by oleate.

Results: The expressions of UCP-1, PGC-1α, ATGL, and CD36 in BAT of DM mice were all downregulated, which could be upregulated by exendin-4 treatment with significant effects on ATGL and CD36. BAT-excision exacerbated high blood glucose (BG) with no significant effect on the serum lipid level. Exendin-4 significantly lowered the level of serum triglycerides (TG) and low-density lipoprotein- (LDL-) c, 24 h urine albumin, and 8-OH-dG; improved renal fibrosis and lipid accumulation; and activated renal AMP-activated protein kinase (AMPK) in diabetic mice regardless of BAT excision. In vitro, there was no significant effect of exendin-4 on brown or white adipogenesis. However, exendin-4 could improve lipid accumulation and myofibroblast-like phenotype transition of mesangial cells induced by oleate via activating the AMPK pathway.

Conclusions: Exendin-4 could decrease the renal lipid deposit and improve diabetic nephropathy via activating the renal AMPK pathway independent of BAT activation.

MeSH terms

  • 3T3-L1 Cells
  • 8-Hydroxy-2'-Deoxyguanosine / urine
  • Adenylate Kinase / metabolism
  • Adipocytes, Brown / drug effects
  • Adipocytes, Brown / metabolism
  • Adipogenesis / drug effects
  • Adipose Tissue, Brown / drug effects*
  • Adipose Tissue, Brown / metabolism
  • Adipose Tissue, Brown / surgery
  • Albuminuria
  • Animals
  • Blood Glucose / drug effects*
  • Blood Glucose / metabolism
  • Blotting, Western
  • Body Weight / drug effects
  • CD36 Antigens / drug effects
  • CD36 Antigens / genetics
  • Cholesterol, HDL / drug effects
  • Cholesterol, HDL / metabolism
  • Cholesterol, LDL / drug effects
  • Cholesterol, LDL / metabolism
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / metabolism*
  • Diabetic Nephropathies / etiology
  • Diabetic Nephropathies / metabolism*
  • Diabetic Nephropathies / pathology
  • Disease Models, Animal
  • Exenatide / pharmacology*
  • Fibrosis
  • Gene Expression / drug effects
  • Incretins / pharmacology*
  • Kidney / drug effects*
  • Kidney / pathology
  • Lipase / drug effects
  • Lipase / genetics
  • Mesangial Cells / drug effects
  • Mesangial Cells / metabolism
  • Mesangial Cells / pathology
  • Mice
  • Mice, Inbred C57BL
  • Myofibroblasts / metabolism
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha / drug effects
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha / genetics
  • Random Allocation
  • Rats
  • Real-Time Polymerase Chain Reaction
  • Triglycerides / metabolism
  • Uncoupling Protein 1 / drug effects
  • Uncoupling Protein 1 / genetics

Substances

  • Blood Glucose
  • CD36 Antigens
  • Cd36 protein, mouse
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Incretins
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
  • Ppargc1a protein, mouse
  • Triglycerides
  • Ucp1 protein, mouse
  • Uncoupling Protein 1
  • 8-Hydroxy-2'-Deoxyguanosine
  • Exenatide
  • Adenylate Kinase
  • Lipase
  • PNPLA2 protein, mouse